A Phase 1 Study of Navlimetostat Tablet Formulations
← catalyst calendarNCT07544628 · readout in 11 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
64estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-27 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Drug: Navlimetostat — also filed as BMS-986504
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax)
measured Up to Day 17
Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
measured Up to Day 17
Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
measured Up to Day 17
Number of participants with Adverse Events (AE)
measured Up to approximately day 37
Number of participants with Serious Adverse Events (AE)
measured Up to approximately day 37
Number of participants with clinically significant changes in Physical Examinations (PE)
measured Up to Day 17
Number of participants with clinically significant changes in vital signs (VS)
measured Up to Day 17
Number of participants with clinically significant changes in 12-lead ECGs
measured Up to Day 17
Number of participants with clinically significant changes in laboratory tests results
measured Up to Day 17
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed